“Laboratory Parameters in Adolescent Patients Aged 12–17 With Moderate-to-Severe Atopic Dermatitis Treated With Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s323, https://doi.org/10.25251/skin.8.supp.323.